Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico

Value in Health Regional Issues

Volumn 8, Issue , 2015, Pages 8-19

  Neslusan, Cheryl ^a   Teschemaker, Anna ^a   Johansen, Pierre ^b   Willis, Michael ^b   Valencia Mendoza, Atanacio ^c   Puig, Andrea ^d  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

^c Janssen Cilag Mexico ^*  (Mexico)

^d JOHNSON AND JOHNSON   (United States)

Author keywords

Cost effectiveness; Dipeptidyl peptidase 4 inhibitor; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; HEMOGLOBIN A1C; METFORMIN; SITAGLIPTIN;

ADD ON THERAPY; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SAFETY; GLYCEMIC CONTROL; GROSS NATIONAL PRODUCT; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SYSTOLIC BLOOD PRESSURE;

EID: 84930614186     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2015.01.002     Document Type: Article

References (72)

1. Obesity prevention in Latin America: now is the time. Lancet Diabetes Endocrinol 2014, 2:263. The Lancet Diabetes Endocrinology.
2. IDF Diabetes Atlas 2013, International Diabetes Federation, International Diabetes Federation, Brussels, Belgium. 6th ed.
3. Corona A.J., Martinez R.R., Villalpando S., SBCA Salinas Diabetes mellitus: La urgente necesidad de reforzar la respuesta en políticas públicas para su prevención y control. Encuesta Nacional de Salud Nutrición 2012, Available from: http://ensanut.insp.mx/doctos/seminario/M0302.pdf. [Accessed May 30, 2014].
4. Barquera S., Campos-Nonato I., Aguilar-Salinas C., et al. Diabetes in Mexico: cost and management of diabetes and its complications and challenges for health policy. Global Health 2013, 9:3.
5. Guzman J.R., Lyra R., Aguilar-Salinas C.A., et al. Treatment of type 2 diabetes in Latin America: a consensus statement by the medical associations of 17 Latin American countries. Latin American Diabetes Association. Rev Panam Salud Publica 2010, 28:463-471.
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853. UK Prospective Diabetes Study (UKPDS) Group.
7. Instituto Mexicano del Seguro Social. Diagnóstico y Tratamiento de la Diabetes Mellitus Tipo 2 México: Guía de Práctica Clinica. Instituto Mexicano del Seguro Social, 2009. Actualización 2012. Instituto Mexicano del Seguro Social 2012. Available from: . [Accessed October 22, 2014]. http://www.imss.gob.mx/sites/all/statics/guiasclinicas/000GER_DiabetesMellitus.pdf.
8. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
9. Ali M.K., Bullard K.M., Saaddine J.B., et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013, 368:1613-1624.
10. Stark Casagrande S., Fradkin J.E., Saydah S.H., et al. The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 2013, 36:2271-2279.
11. Villalpando S., de la Cruz V., Rojas R., et al. Prevalence and distribution of type 2 diabetes mellitus in Mexican adult population: a probabilistic survey. Salud Publica Mex 2010, 52(Suppl. 1):S19-S26.
12. Barquera S., Campos-Nonato I., Hernandez-Barrera L., et al. Hypertension in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Publica Mex 2010, 52(Suppl. 1):S63-S71.
13. Aguilar-Salinas C.A., Gomez-Perez F.J., Rull J., et al. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex 2010, 52(Suppl. 1):S44-S53.
14. Gomez L.M., Hernandez-Prado B., Morales M.C., Shamah-Levy T. Physical activity and overweight/obesity in adult Mexican population: the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex 2009, 51(Suppl. 4):S621-S629.
15. Johnson & Johnson, Inc. New long-term data show INVOKANA® (canagliflozin) lowers blood glucose in older patients with type 2 diabetes inadequately controlled on other therapies. 2014. Available from: . [Accessed October 20, 2014]. http://www.jnj.com/news/all/New-Long-Term-Data-Show-INVOKANA-canagliflozin-Lowers-Blood-Glucose-in-Older-Patients-with-Type-2-Diabetes-Inadequately-Controlled-on-Other-Therapies.
16. INVOKANA® (canagliflozin) tablets, for oral use [package insert] 2013, Janssen Pharmaceuticals, Titusville, NJ.
17. INVOKANA. Informacion Para Prescribir Amplia INVOKANA® F.F Tableta V1.0 CCDS Junio. 2012.
18. Bode B., Stenlöf K., Sullivan D., et al. Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013, 41:72-84.
19. Cefalu W.T., Leiter L.A., Yoon K.-H., et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 2013, 382:941-950.
20. Lavalle-González F.J., Januszewicz A., Davidson J., et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013, 56:2582-2592.
21. Schernthaner G., Gross J.L., Rosenstock J., et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week, randomized trial. Diabetes Care 2013, 36:2508-2515.
22. Stenlöf K., Cefalu W.T., Kim K.A., et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin 2014, 30:163-175.
23. Stenlöf K., Cefalu W.T., Kim K.-A., et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013, 15:372-382.
24. Wilding J.P., Charpentier G., Hollander P., et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 2013, 67:1267-1282.
25. Yale J.F., Bakris G., Cariou B., et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013, 15:463-473.
26. Forst T., Guthrie R., Goldenberg R., et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014, 16:467-477.
27. Cefalu W.T., Leiter L.A., Yoon K.-H., et al. Canagliflozin demonstrates durable glycemic improvements over 104 weeks versus glimepiride in subjects with type 2 diabetes mellitus on metformin. Poster presented at: the 73rd Scientific Sessions of the American Diabetes Association (ADA) June 21-25, 2013, (Chicago, IL).
28. Standards of medical care in diabetes-2014. Diabetes Care 2014, 37(Suppl. 1):S14-S80. American Diabetes Association.
29. Palmer A.J. The Mount Hood 5 Modeling Group. Computer modeling of diabetes and its complications: a report on the fifth Mount Hood Challenge meeting. Value Health 2013, 16:670-685.
30. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004, 27:2262-2265. American Diabetes Association.
31. Mexican Peso exchange rate - US dollar - Historical exchange rates. 2014. Available from: . [Accessed October 22, 2014]. http://www.exchange-rates.org/history/MXN/USD/T.
32. Quintiles Consulting, van Engen A, Heemstra L. The challenges of introducing HTA in Latin America. HTA Uncovered 2014;(5):1-9.
33. Rizo Rios P., Gonzalez Rivera A., Rivas Oropeza I., Rivas Bocanegra R.E. Análisis del Proceso de Actualización de Medicamentos en el Cuadro Básico y Catálogo de Insumos del Sector Salud. Value Health Regional 2013, 3. 387-291.
34. World Health Organization. Cost-effectiveness thresholds. Available from: . [Accessed October 21, 2014]. http://www.who.int/choice/costs/CER_thresholds/en/.
35. Willis M., Asseburg C., He J. Validation of economic and health outcomes simulation model of type 2 diabetes mellitus (ECHO-T2DM). J Med Econ 2013, 16:1007-1021.
36. Rojas R., Aguilar-Salinas C., Jimenez-Corona A., et al. Metabolic syndrome in Mexican adults: results from the National Health and Nutrition Survey 2006. Salud Pública Méx 2010, 52(Supp1.):11-18.
37. Brown J.B., Russell A., Chan W., et al. The global diabetes model: user friendly version 3.0. Diabetes Res Clin Pract 2000, 50(Suppl. 3):S15-S46.
38. Bagust A., Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ 2005, 14:217-230.
39. Eastman R.C., Javitt J.C., Herman W.H., et al. Model of complications of NIDDM, II: analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 1997, 20:735-744.
40. Hoerger T.J., Wittenborn J.S., Segel J.E., et al. A health policy model of CKD, 1: model construction, assumptions, and validation of health consequences. Am J Kidney Dis 2010, 55:452-462.
41. Clarke P.M., Gray A.M., Briggs A., et al. A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68). Diabetologia 2004, 47:1747-1759.
42. Hayes A.J., Leal J., Gray A.M., et al. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia 2013, 56:1925-1933.
43. Zethelius B., Eliasson B., Eeg-Olofsson K., et al. A new model for 5-year risk of cardiovascular disease in type 2 diabetes, from the Swedish National Diabetes Register (NDR). Diabetes Res Clin Pract 2011, 93:276-284.
44. Chaudhry Z.W., Gannon M.C., Nuttall F.Q. Stability of body weight in type 2 diabetes. Diabetes Care 2006, 29:493-497.
45. Janssen Research & Development. Integrated summary of efficacy: canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. 2012.
46. JANUVIA® (sitagliptin) tablets [package insert] 2012, Merck & Co., Inc., Whitehouse Station, NJ.
47. Nyirjesy P., Sobel J.D., Fung A., et al. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin 2014, 30:1109-1119.
48. Nicolle L.E., Capuano G., Fung A., Usiskin K. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor. Postgrad Med 2014, 126:7-17.
49. Weir M., Januszewicz A., Gilbert R., et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2014, 16:875-882.
50. Janssen Research & Development. Integrated summary of safety. Canagliflozin as an adjunctive treatment to diet and exercise alone or co-administered with other antihyperglycemic agents to improve glycemic control in adults with type 2 diabetes mellitus. Raritan, NJ: Janssen Research & Development, 2012.
51. Meier J.J., Nauck M.A. Risk of pancreatitis in patients treated with incretin-based therapies. Diabetologia 2014, 57:1320-1324.
52. Instituto Mexicano del Seguro Social. Diagnostico y Tratamiento de la Diabetes Mellitus Tipo 2. Guía de Referencia Rápida. México: Instituto Mexicano del Seguro Social, 2009. Actualización 2012. Instituto Mexicano del Seguro Social 2012. Available from: . [Accessed May 27, 2014]. http://www.imss.gob.mx/sites/all/statics/guiasclinicas/000GRR_DiabetesMellitus.pdf.
53. Law M.R., Morris J.K., Wald N.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009, 338:b1665.
54. Brown W.V., Bays H.E., Hassman D.R., et al. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J 2002, 144:1036-1043.
55. Wolffenbuttel B.H., Franken A.A., Vincent H.H. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes -- CORALL study. J Intern Med 2005, 257:531-539.
56. Centro Nacional de Excelencia Tecnológica en Salud. Evaluación de Tecnologías de la Salud, Documento metodológico. Available from: http://www.cenetec.salud.gob.mx/descargas/detes/Documento_metodologico_ETES.pdf. [Accessed October 22, 2014].
57. Ríos P.R., Rivera A.G., Oropeza I.R. Bocanegra RER. Análisis del Proceso de Actualización de Medicamentos en el Cuadro Básico y Catálogo de Insumos del Sector Salud. Value Health 2013, 2:387-391.
58. Rosenstock J., Davies M., Home P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008, 51:408-416.
59. Riddle M.C., Vlajnic A., Zhou R., Rosenstock J. Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulin glargine in type 2 diabetes: a patient-level analysis of 12 studies. Diabetes Obes Metab 2013, 15:819-825.
60. Fonseca V., Gill J., Zhou R., Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011, 13:814-822.
61. Lopez-Cervantes M., Rojas-Russell M.E., Tirado-Gomez L.L., et al. Enfermedad renal crónica y su atención mediante tratamiento sustitutivo en México 2009, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico.
62. Instituto de Seguridad y Servivios Sociales de los Trabajadores del Estado. Tabulador de no derechohabientes 2012, Dirección Médica, Subdirección de Regulación y Atención Hospitalaria, Jefatura de Servicios, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado. ISSSTE, 2012.
63. Costos directos de complicaciones relacionadas con la diabetes en México. Internal report by IMS. 2013.
64. Instituto Nacional de Cancerología INCAN. Tabulador de Cuotas de Recuperación, Subsecretaría de Ingresos, Unidad de política de ingresos. 2012. Available from: . [Accessed May 30, 2014]. http://www.policiabancaria.df.gob.mx/portal_pbi/articulo15/fraccion8/2012/24%20Instituto%20Nacional%20de%20Cancerolog%C3%ADa%20POLICIA%20BANCARIA%20INCAN%202012.pdf.
65. Hospital General de Mexico. Tabulador de Cuotas de Recuperación, 2012. 2012. Available from: . [Accessed May 30, 2014]. http://www.policiabancaria.df.gob.mx/portal_pbi/articulo15/fraccion8/2012/19%20Hospital%20General%20de%20M%C3%A9xico%202012.pdf.
66. Comisión Interinstitucional del Cuadro Básico de Insumos del Sector Salud. Cuadro básico y catálogo de medicamentos. 2012. Available from: . [Accessed May 30, 2014]. http://www.dof.gob.mx/nota_detalle.php?codigo=5299596&fecha=21/05/2013.
67. Instituto Mexicano del Seguro Social. Portal de compras del IMSS. Instituto Mexicano del Seguro Social. 2014. Available from: http://compras.imss.gob.mx. [Accessed May 30, 2014].
68. Indice Nacional de Precios al Consumidor, Servicio de Administración Tributaria. 2014. Available from: . [Accessed May 30, 2014]. http://www.sat.gob.mx/informacion_fiscal/tablas_indicadores/Paginas/inpc_2012.aspx.
69. Evans M., Khunti K., Mamdani M., et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes 2013, 11:90.
70. Shingler S., Fordham B., Evans M., et al. Utilities for treatment-related adverse events in type 2 diabetes. J Med Econ 2015, 18:45-55.
71. Coyne K.S., Sexton C.C., Irwin D.E., et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008, 101:1388-1395.
72. Lane S., Levy A.R., Mukherjee J., et al. The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes. Curr Med Res Opin 2014, 30:1267-1273.